NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis $27.39 +1.06 (+4.03%) Closing price 04:00 PM EasternExtended Trading$27.41 +0.02 (+0.07%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About QuidelOrtho Stock (NASDAQ:QDEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get QuidelOrtho alerts:Sign Up Key Stats Today's Range$26.01▼$27.4250-Day Range$25.30▼$32.5752-Week Range$23.77▼$49.45Volume1.16 million shsAverage Volume1.78 million shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice Target$44.33Consensus RatingHold Company Overview QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. Read More QuidelOrtho Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreQDEL MarketRank™: QuidelOrtho scored higher than 89% of companies evaluated by MarketBeat, and ranked 112th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageQuidelOrtho has only been the subject of 2 research reports in the past 90 days.Read more about QuidelOrtho's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.57% Earnings GrowthEarnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -5.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about QuidelOrtho's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.75% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 44.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.61 Percentage of Shares Shorted8.75% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 44.23%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.90 News SentimentQuidelOrtho has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for QuidelOrtho this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesUrgent Need for Early Detection in Drug Overdose Cases Highlighted in New PodcastJuly 24 at 9:00 AM | prnewswire.comQuidelOrtho Corp (QDEL) Announces Second Quarter 2025 Financial Results Release | QDEL stock newsJuly 22 at 5:25 PM | gurufocus.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 25 at 2:00 AM | Brownstone Research (Ad)QuidelOrtho to Report Second Quarter 2025 Financial ResultsJuly 22 at 4:30 PM | prnewswire.comQuidelOrtho Corporation (NASDAQ:QDEL) Receives $44.33 Consensus Target Price from BrokeragesJuly 22 at 2:25 AM | americanbankingnews.comReal Labs, Actual Decisions With Actionable Six Sigma MetricsJuly 17, 2025 | prnewswire.comRBC Capital Maintains a Buy Rating on QuidelOrtho Corporation (QDEL), Sets a $60 PTJuly 16, 2025 | insidermonkey.comQUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)July 14, 2025 | prnewswire.comSee More Headlines QDEL Stock Analysis - Frequently Asked Questions How have QDEL shares performed this year? QuidelOrtho's stock was trading at $44.55 at the start of the year. Since then, QDEL stock has decreased by 38.5% and is now trading at $27.39. How were QuidelOrtho's earnings last quarter? QuidelOrtho Corporation (NASDAQ:QDEL) announced its quarterly earnings data on Wednesday, May, 7th. The company reported $0.74 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.13. The business's revenue was down 2.6% compared to the same quarter last year. Read the conference call transcript. Who are QuidelOrtho's major shareholders? QuidelOrtho's top institutional investors include Assenagon Asset Management S.A. (1.39%), Gagnon Securities LLC (0.11%), Moody National Bank Trust Division (0.08%) and CWM LLC (0.06%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2025Today7/25/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees6,600Year Founded1979Price Target and Rating Average Price Target for QuidelOrtho$44.33 High Price Target$61.00 Low Price Target$25.00 Potential Upside/Downside+62.2%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.97) Trailing P/E RatioN/A Forward P/E Ratio11.88 P/E GrowthN/ANet Income-$2.05 billion Net Margins-12.07% Pretax Margin-12.35% Return on Equity4.71% Return on Assets2.21% Debt Debt-to-Equity Ratio0.70 Current Ratio1.20 Quick Ratio0.66 Sales & Book Value Annual Sales$2.78 billion Price / Sales0.66 Cash Flow$36.43 per share Price / Cash Flow0.75 Book Value$44.38 per share Price / Book0.62Miscellaneous Outstanding Shares67,630,000Free Float67,092,000Market Cap$1.85 billion OptionableOptionable Beta0.07 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:QDEL) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.